Prelude Therapeutics Inc
PRLD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$224.57M
Close$
$1.02
73.4% downside
Current Fair Value
73.4% downsideOvervalued by 73.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $224.57 Million |
|---|---|
| Enterprise Value | $241.14 Million |
| Earnings per Share | $-1.29 |
| Beta | 0.96 |
| Outstanding Shares | 98,388,593 |
Return
| Return on Equity | -45.23% |
|---|---|
| Return on Assets | -31.94% |
| Return on Invested Capital | -43.07% |
Valuation & Multiples
| P/E Ratio | -4.91 |
|---|---|
| PEG | 8.86 |
| Price to Sales | - |
| Price to Book Ratio | 3.84 |
| Enterprise Value to Revenue | 10.75 |
| Enterprise Value to EBIT | -3.7 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.23
Consensus analyst estimateRevenue Estimate
$6.14 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.11
Consensus analyst estimateRevenue Estimate
$35.33 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 60.20% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 50.45% |
|---|---|
| Total Invested | $106,255▼ 99.96% |
| Investors Holding | 4▼ 79.00% |
About Prelude Therapeutics Inc
68 employees
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhib...